Charles Schwab’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.82B | Sell |
12,967,398
-12,202,446
| -48% | -$2.71B | 0.43% | 44 |
|
|
2025
Q4 | $5.75B | Sell |
25,169,844
-788,262
| -3% | -$180M | 0.89% | 15 |
|
|
2025
Q3 | $6.01B | Sell |
25,958,106
-825,223
| -3% | -$168M | 0.96% | 12 |
|
|
2025
Q2 | $4.97B | Buy |
26,783,329
+1,519,397
| +6% | +$282M | 0.86% | 20 |
|
|
2025
Q1 | $5.29B | Sell |
25,263,932
-2,172,201
| -8% | -$422M | 0.99% | 14 |
|
|
2024
Q4 | $4.88B | Buy |
27,436,133
+3,599,336
| +15% | +$662M | 0.9% | 17 |
|
|
2024
Q3 | $4.71B | Sell |
23,836,797
-1,137,780
| -5% | -$212M | 0.9% | 16 |
|
|
2024
Q2 | $4.28B | Buy |
24,974,577
+2,257,263
| +10% | +$374M | 0.82% | 19 |
|
|
2024
Q1 | $4.12B | Sell |
22,717,314
-1,734,661
| -7% | -$299M | 0.95% | 11 |
|
|
2023
Q4 | $3.77B | Buy |
24,451,975
+1,702,415
| +7% | +$248M | 0.96% | 12 |
|
|
2023
Q3 | $3.39B | Sell |
22,749,560
-47,492
| -0.2% | -$6.97M | 0.97% | 15 |
|
|
2023
Q2 | $3.07B | Buy |
22,797,052
+1,260,396
| +6% | +$185M | 0.88% | 20 |
|
|
2023
Q1 | $3.43B | Buy |
21,536,656
+12,515,744
| +139% | +$1.91B | 1.04% | 12 |
|
|
2022
Q4 | $1.46B | Buy |
9,020,912
+101,354
| +1% | +$15.5M | 0.47% | 39 |
|
|
2022
Q3 | $1.2B | Buy |
8,919,558
+101,395
| +1% | +$14.6M | 0.43% | 38 |
|
|
2022
Q2 | $1.35B | Sell |
8,818,163
-86,825
| -1% | -$13.3M | 0.47% | 35 |
|
|
2022
Q1 | $1.44B | Buy |
8,904,988
+176,026
| +2% | +$25.6M | 0.43% | 37 |
|
|
2021
Q4 | $1.18B | Buy |
8,728,962
+172,972
| +2% | +$20.4M | 0.35% | 55 |
|
|
2021
Q3 | $923M | Buy |
8,555,990
+34,669
| +0.4% | +$3.96M | 0.3% | 65 |
|
|
2021
Q2 | $960M | Buy |
8,521,321
+99,678
| +1% | +$11.2M | 0.32% | 61 |
|
|
2021
Q1 | $911M | Buy |
8,421,643
+275,867
| +3% | +$29.5M | 0.33% | 57 |
|
|
2020
Q4 | $873M | Buy |
8,145,776
+17,063
| +0.2% | +$1.64M | 0.35% | 54 |
|
|
2020
Q3 | $712M | Sell |
8,128,713
-329,940
| -4% | -$31.1M | 0.33% | 57 |
|
|
2020
Q2 | $830M | Buy |
8,458,653
+1,422,400
| +20% | +$125M | 0.41% | 49 |
|
|
2020
Q1 | $536M | Buy |
7,036,253
+95,964
| +1% | +$8.17M | 0.31% | 61 |
|
|
2019
Q4 | $614M | Buy |
6,940,289
+228,584
| +3% | +$19M | 0.33% | 50 |
|
|
2019
Q3 | $508M | Buy |
6,711,705
+98,619
| +1% | +$6.76M | 0.3% | 60 |
|
|
2019
Q2 | $481M | Buy |
6,613,086
+182,795
| +3% | +$14.4M | 0.29% | 62 |
|
|
2019
Q1 | $518M | Buy |
6,430,291
+2,246
| +0% | +$184K | 0.33% | 54 |
|
|
2018
Q4 | $593M | Buy |
6,428,045
+164,955
| +3% | +$14.5M | 0.45% | 39 |
|
|
2018
Q3 | $592M | Buy |
6,263,090
+262,893
| +4% | +$24.9M | 0.39% | 43 |
|
|
2018
Q2 | $556M | Sell |
6,000,197
-87,819
| -1% | -$8.58M | 0.41% | 41 |
|
|
2018
Q1 | $576M | Buy |
6,088,016
+220,125
| +4% | +$24.2M | 0.45% | 36 |
|
|
2017
Q4 | $567M | Buy |
5,867,891
+358,209
| +7% | +$33.8M | 0.45% | 38 |
|
|
2017
Q3 | $490M | Buy |
5,509,682
+283,566
| +5% | +$21.6M | 0.43% | 40 |
|
|
2017
Q2 | $379M | Buy |
5,226,116
+89,442
| +2% | +$6.01M | 0.36% | 43 |
|
|
2017
Q1 | $335M | Buy |
5,136,674
+130,740
| +3% | +$8.22M | 0.34% | 46 |
|
|
2016
Q4 | $313M | Buy |
5,005,934
+105,607
| +2% | +$6.45M | 0.34% | 44 |
|
|
2016
Q3 | $309M | Buy |
4,900,327
+12,167
| +0.2% | +$788K | 0.36% | 45 |
|
|
2016
Q2 | $303M | Sell |
4,888,160
-32,778
| -0.7% | -$2M | 0.38% | 46 |
|
|
2016
Q1 | $281M | Buy |
4,920,938
+118,225
| +2% | +$6.59M | 0.37% | 48 |
|
|
2015
Q4 | $285M | Sell |
4,802,713
-188,360
| -4% | -$10.8M | 0.38% | 50 |
|
|
2015
Q3 | $272M | Sell |
4,991,073
-178,769
| -3% | -$11.6M | 0.4% | 46 |
|
|
2015
Q2 | $347M | Buy |
5,169,842
+891,070
| +21% | +$58.2M | 0.48% | 33 |
|
|
2015
Q1 | $250M | Buy |
4,278,772
+32,937
| +0.8% | +$1.99M | 0.35% | 53 |
|
|
2014
Q4 | $278M | Sell |
4,245,835
-333,494
| -7% | -$21M | 0.42% | 42 |
|
|
2014
Q3 | $265M | Sell |
4,579,329
-61,518
| -1% | -$3.42M | 0.44% | 40 |
|
|
2014
Q2 | $262M | Buy |
4,640,847
+29,655
| +0.6% | +$1.56M | 0.44% | 40 |
|
|
2014
Q1 | $237M | Buy |
4,611,192
+124,724
| +3% | +$6.3M | 0.43% | 42 |
|
|
2013
Q4 | $237M | Sell |
4,486,468
-1,072
| -0% | -$52.7K | 0.45% | 42 |
|
|
2013
Q3 | $206M | Buy |
4,487,540
+276,530
| +7% | +$12.3M | 0.42% | 42 |
|
|
2013
Q2 | $175M | Buy |
+4,211,010
| New | +$184M | 0.39% | 43 |
|
Other funds holding ABBV
VCM
VPM
Charles Schwab's ABBV Position: Q1 2026 in Review
Charles Schwab reduced its AbbVie (ABBV) stake by 48% in Q1 2026, selling an estimated $2.71B and leaving 12,967,398 shares worth $2.82B. The position accounts for 0.43% of the portfolio, ranked #44.
Charles Schwab first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.01B in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Charles Schwab held 12,967,398 shares of AbbVie worth $2.82B as of Q1 2026.
- Charles Schwab sold 12,202,446 AbbVie shares in Q1 2026, an estimated $2.71B.
- AbbVie made up 0.43% of Charles Schwab's portfolio in Q1 2026, its #44 holding.
- Charles Schwab first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Charles Schwab's AbbVie position peaked at $6.01B in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.